Filariasis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 27: | Line 27: | ||
==Treatment== | ==Treatment== | ||
[[Filariasis medical therapy|Medical Therapy]] | [[Filariasis primary prevention|Primary Prevention]] | [[Filariasis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Filariasis future or investigational therapies|Future or Investigational Therapies]] | [[Filariasis medical therapy|Medical Therapy]] | [[Filariasis primary prevention|Primary Prevention]] | [[Filariasis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Filariasis future or investigational therapies|Future or Investigational Therapies]] | ||
===Antimicrobial therapy=== | |||
:* '''Filariasis treatment''' | |||
::* 1. '''Lymphatic filariasis - Wuchereria bancrofti, Brugia malayi Brugia timori'''<ref name="pmid20739055">{{cite journal| author=Taylor MJ, Hoerauf A, Bockarie M| title=Lymphatic filariasis and onchocerciasis. | journal=Lancet | year= 2010 | volume= 376 | issue= 9747 | pages= 1175-85 | pmid=20739055 | doi=10.1016/S0140-6736(10)60586-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20739055 }} </ref><ref name="pmid22632644">{{cite journal| author=Knopp S, Steinmann P, Hatz C, Keiser J, Utzinger J| title=Nematode infections: filariases. | journal=Infect Dis Clin North Am | year= 2012 | volume= 26 | issue= 2 | pages= 359-81 | pmid=22632644 | doi=10.1016/j.idc.2012.02.005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22632644 }} </ref> | |||
:::* Preferred regimen: [[Diethylcarbamazine]] 6 mg/day PO qd for 12 days (single dose if patient will continue to live in endemic area or is younger than 9 years old) {{with or without}} [[Albendazole]] 400 mg PO qd | |||
:::* Alternative regimen: [[Doxycycline]] 200 mg/day for 4 weeks {{with or without}} [[Ivermectin]] 150 μg/kg single dose (do not administer [[Ivermectin]] if there's a risk of serious adverse effects in areas where Loa loa is coendemic) | |||
:::* Note: Do not administer [[Diethylcarbamazine]] where onchocerciasis is endemic due to the risk of causing severe local inflammation in patients with ocular microfilariae. | |||
::* 2. '''Cutaneous filariasis - Onchocercia volvulus, Loa loa'''<ref name="pmid20739055">{{cite journal| author=Taylor MJ, Hoerauf A, Bockarie M| title=Lymphatic filariasis and onchocerciasis. | journal=Lancet | year= 2010 | volume= 376 | issue= 9747 | pages= 1175-85 | pmid=20739055 | doi=10.1016/S0140-6736(10)60586-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20739055 }} </ref><ref name="pmid22632644">{{cite journal| author=Knopp S, Steinmann P, Hatz C, Keiser J, Utzinger J| title=Nematode infections: filariases. | journal=Infect Dis Clin North Am | year= 2012 | volume= 26 | issue= 2 | pages= 359-81 | pmid=22632644 | doi=10.1016/j.idc.2012.02.005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22632644 }} </ref> | |||
:::* Preferred regimen (1): [[Doxycycline]] 150 μg/kg single dose | |||
:::* Preferred regimen (2): ([[Doxycycline]] 100 mg PO qd for 6 weeks {{or}} 200 mg PO qd for 4 weeks) {{then}} [[Ivermectin]] after 4-6 months 150 μg/kg single dose; {{or}} [[Doxycycline]] 200 mg PO qd for 6 weeks {{then}} [[Ivermectin]] after 4-6 months 150 μg/kg single dose | |||
==Case Studies== | ==Case Studies== | ||
| Line 52: | Line 61: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
==References== | |||
{{reflist|2}} | |||
Revision as of 15:47, 29 July 2015
| Filariasis | |
 |
|---|
|
Filariasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Filariasis On the Web |
|
American Roentgen Ray Society Images of Filariasis |
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Filariasis from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Primary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Antimicrobial therapy
- Filariasis treatment
-
- Preferred regimen: Diethylcarbamazine 6 mg/day PO qd for 12 days (single dose if patient will continue to live in endemic area or is younger than 9 years old) Template:With or without Albendazole 400 mg PO qd
- Alternative regimen: Doxycycline 200 mg/day for 4 weeks Template:With or without Ivermectin 150 μg/kg single dose (do not administer Ivermectin if there's a risk of serious adverse effects in areas where Loa loa is coendemic)
- Note: Do not administer Diethylcarbamazine where onchocerciasis is endemic due to the risk of causing severe local inflammation in patients with ocular microfilariae.
- Preferred regimen (1): Doxycycline 150 μg/kg single dose
- Preferred regimen (2): (Doxycycline 100 mg PO qd for 6 weeks OR 200 mg PO qd for 4 weeks) THEN Ivermectin after 4-6 months 150 μg/kg single dose; OR Doxycycline 200 mg PO qd for 6 weeks THEN Ivermectin after 4-6 months 150 μg/kg single dose
Case Studies
Case #1 Template:Helminthiases
ar:فلاريا de:Filariose it:Filariosi ms:Penyakit Untut nl:Filariasis sk:Vlásovce wa:fiyaires
References
- ↑ 1.0 1.1 Taylor MJ, Hoerauf A, Bockarie M (2010). "Lymphatic filariasis and onchocerciasis". Lancet. 376 (9747): 1175–85. doi:10.1016/S0140-6736(10)60586-7. PMID 20739055.
- ↑ 2.0 2.1 Knopp S, Steinmann P, Hatz C, Keiser J, Utzinger J (2012). "Nematode infections: filariases". Infect Dis Clin North Am. 26 (2): 359–81. doi:10.1016/j.idc.2012.02.005. PMID 22632644.